Earnings ·
BioCryst Pharmaceuticals reported second quarter 2026 financial results with total net revenue of $218.3 million and…
BCRXBiocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals reported second quarter 2026 financial results with total net revenue of $218.3 million and ORLADEYO net revenue of $158.2 million. The company achieved a GAAP operating profit of $98.5 million and recognized $55.7 million in license revenue from its navenibart European rights agreement. BioCryst raised its full year 2026 total revenue guidance to $690–$715 million while maintaining ORLADEYO revenue guidance at $625–$645 million. Key operational updates include the commencement of ORLADEYO oral pellet shipments to pediatric patients on August 3, the completion of enrollment in the pivotal ALPHA-ORBIT navenibart study, and the appointment of David W. Jenkins as Chief Scientific Officer. The company operates in the biotechnology industry, focusing on developing and commercializing medicines for hereditary angioedema and other rare diseases.